Dengue hemorrhagic fever (DBD) is projected to impose an economic burden of IDR 9 trillion on Indonesia by 2024, with over 2 million hospitalizations expected. According to Gadjah Mada University (UGM) research, this includes IDR 3 trillion in direct service costs covered by BPJS Kesehatan and IDR 3.5 trillion in out-of-pocket expenses and lost productivity for families. Rising temperatures linked to El Niño events are expected to further accelerate the transmission cycle of the Aedes aegypti mosquito.
Why Is the Economic Impact of Dengue Rising?
The financial strain of dengue extends far beyond hospital bills. While the Health Social Security Agency (BPJS Kesehatan) covers a significant portion of treatment costs, families remain vulnerable to substantial hidden expenses. Research from UGM highlights that for every IDR 3 trillion paid by the state, patients lose an additional IDR 3.5 trillion in income and direct non-medical expenditures. This gap creates a cycle of financial instability for households, particularly when the primary breadwinner or a child requires extended clinical care.
How Will Climate Change Affect Transmission Rates?
Climate scientists project an 80 percent probability of an El Niño event between June and August 2026, with the likelihood rising above 90 percent by year-end. According to the Ministry of Health (Kemenkes), these shifts in rainfall and air temperature expand the breeding habitats of Aedes aegypti. As habitats grow, the life cycle of the mosquito accelerates, leading to higher viral loads in urban centers like Jakarta. The city, which recorded 5,700 cases by mid-June 2026, remains a focal point for these environmental pressures due to its high population density.
Who Is Most at Risk of Severe Complications?
Dengue is no longer just a pediatric concern. While the highest mortality rate in 2025 was recorded among children aged 5–14 (41%), the highest volume of cases occurred in the 15–44 age group (42%). Comorbidities significantly worsen patient outcomes. Data provided by Dr. dr. Sukamto Koesnoe of the Indonesian Society of Internal Medicine (PAPDI) reveals that patients with existing conditions face drastically higher risks:
- Hypertension: 2–3 times higher risk of complications.
- Diabetes Mellitus: 3–5 times higher risk.
- Kidney Disease: 7 times higher risk.
- Asthma or Chronic Lung Disease: 2–12 times higher risk.
What Are the Latest Recommendations for Prevention?
The Ministry of Health is shifting toward a collaborative model under the National Strategy (Stranas) for Dengue Control 2021-2025. Dr. Agus Handita of the Kemenkes Arbovirosis Working Team emphasizes that the strategy relies on the 3MPlus method—draining, closing, and recycling water containers—alongside modern medical interventions. Furthermore, the Indonesian Paediatric Society (IDAI) and PAPDI have both issued guidance recommending vaccination to reduce the risk of hospitalization and life-threatening conditions like dengue shock.
Frequently Asked Questions
Is the dengue vaccine recommended for adults?
Yes. PAPDI recommends the vaccine for individuals aged 18–60, particularly those with comorbidities who face a higher risk of severe complications, as stated by Dr. dr. Sukamto Koesnoe.
What is the 3MPlus strategy?
The 3MPlus strategy is a government-backed initiative involving three core actions: draining water storage, closing water containers, and recycling used items that might hold stagnant water, plus additional preventative measures like using mosquito repellent.
How does El Niño impact dengue in Indonesia?
El Niño alters rainfall and temperature patterns, which can expand the geographic range of Aedes aegypti mosquitoes and shorten their reproductive cycle, leading to more frequent outbreaks.
Are you concerned about dengue risks in your neighborhood? Share your thoughts in the comments below or subscribe to our health newsletter for the latest updates on disease prevention and national health policy.
